NASDAQ · Biotechnology

Pyxis Oncology, Inc. (PYXS) Stock

$2.03 +2.01% NASDAQ: PYXS Healthcare

Valuation

MetricValue
Price$2.03
Market Cap$128.61M
P/E Ratio-1.52
P/B Ratio11.97
P/S Ratio12.28
EPS (TTM)$-1.28
52-Week High$5.55
52-Week Low$1.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-215.23%
ROA-161.55%
ROCE-335.57%
Gross Margin-600.00%
Operating Margin-600.00%
Net Margin-803.83%
Debt/Equity1.56
Current Ratio3.43

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$16.0M$14.0M
Operating Profit$-70.0M$-123.0M$-82.0M$-89.0M$-84.0M
Net Profit$-76.0M$-121.0M$-74.0M$-77.0M$-80.0M
EPS$-2.53$-3.57$-1.85$-1.32$-1.28
Op Margin———-554.1%-609.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$280.0M$211.0M$174.0M$157.0M$92.0M
Total Liabilities$19.0M$51.0M$48.0M$36.0M$38.0M
Cash$275.0M$179.0M$10.0M$19.0M$15.0M
Borrowings$0$19.0M$21.0M$20.0M$19.0M

Latest News

Pyxis Oncology Secures Up to $114 Million Private Placement MT Newswires · Jun 30, 2026 Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones GlobeNewswire · Jun 30, 2026 Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS) Insider Monkey · Jun 10, 2026 Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones GlobeNewswire · May 14, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences GlobeNewswire · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-35.0M$-89.0M$-71.0M$-58.0M$-64.0M
Investing Cash Flow$-1.0M$-13.0M$-112.0M$8.0M$59.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$268.0M$-96.0M$-170.0M$10.0M$-4.0M
Free Cash Flow$-36.0M$-96.0M$-77.0M$-58.0M$-64.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.20
EV / EBITDA-1.61
FCF Yield-50.09%
Quick Ratio1.34
Interest Coverage0.00
Return 1Y92.44%
Return 3Y-13.58%
Return 5Y—

Ownership

Insiders Held13.60%
Institutions Held42.45%
Institutions Float Held49.13%
Institutional HolderSharesReport Date
Pfizer Inc7,032,7702026-03-31
Laurion Capital Management, LP4,997,3332026-03-31
GordonMD Global Investments LP4,121,8702026-03-31
Vanguard Capital Management LLC2,033,5102026-03-31
Palo Alto Investors Lp1,010,5102026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVIRAtea Pharmaceuticals, Inc. $5.14 -0.35% -2.47 $411.08M 0.00%
CRBUCaribou Biosciences, Inc. $0.48 -0.52% -1.13 $47.48M 0.00%
ENTAEnanta Pharmaceuticals, Inc. $12.50 +3.31% -5.32 $363.48M 0.00%
FHTXFoghorn Therapeutics Inc. $2.00 +0.50% -2.11 $117.43M 0.00%
HUMAHumacyte, Inc. $0.41 -9.35% -1.00 $68.09M 0.00%

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is led by CEO Thomas Civik, employs 44 people, headquartered in US, publicly traded since 2021.

Pyxis Oncology, Inc. (PYXS) stock trades at $2.03 with a market capitalization of $128.61M. The stock is valued at a price-to-earnings (P/E) ratio of -1.52, price-to-book of 11.97, price-to-sales of 12.28. Over the past 52 weeks the stock has ranged between $1.03 and $5.55, and currently trades 63.4% below its 52-week high.

On profitability, Pyxis Oncology, Inc. generates a return on equity (ROE) of -215.23%, return on capital employed of -335.57%, an operating margin of -600.00%, a net profit margin of -803.83%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides